Skip to content

Value of contrast-enhanced ultrasound in locating and diagnosing sentinel lymph nodes in breast cancer patients

Value of contrast-enhanced ultrasound in locating and diagnosing sentinel lymph nodes in breast cancer patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057903
Enrollment
Unknown
Registered
2022-03-21
Start date
2019-06-13
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Take pathological results as the gold standard. According to breast cancer staging criteria the American Joint Committee on Cancer: macro-metastases refer to metastases with a maximum di
Index test:The contrast-enhanced ultrasound examination instruments are Siemens ACUSON Sequoia Redwood ultrasonic diagnostic instrument (10 L4 linear array probe), Mindray Resona 7 (l9-3 linear array

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with breast cancer; 2. Perform contrast-enhanced ultrasound and sentinel lymph node puncture or biopsy.

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone axillary surgery; 2. Patients with a history of ultrasound contrast agent allergy.

Design outcomes

Primary

MeasureTime frame
Characteristics of percutaneous contrast-enhanced ultrasonography in sentinel lymph nodes;Characteristics of sentinel lymph nodes by intravenous contrast-enhanced ultrasonography;Pathological features of sentinel lymph nodes;Conventional ultrasound features of sentinel lymph nodes;Ultrasonographic features of breast cancer;

Secondary

MeasureTime frame
Pathological types of breast cancer;Expression level of estrogen receptor in breast cancer;Expression level of progesterone receptor in breast cancer;Expression level of Ki-67 in breast cancer;Expression level of Her-2 in breast cancer;Pathological grading of breast cancer;

Countries

China

Contacts

Public ContactYanling Zheng

The First Affiliated Hospital of Sun Yat-sen University

zhyanl@mail.sysu.edu.cn+86 13725287157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026